FIELD: medicine.
SUBSTANCE: invention relates to treatment of diabetic retinopathy. Disclosed is use of a compound of formula (I) or salt thereof to prevent, treat and/or reduce macular edema caused by or associated with diabetic retinopathy.
EFFECT: technical result consists in realising claimed purpose.
6 cl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
LOCAL EYE PEPTIDE COMPOSITION | 2010 |
|
RU2561585C2 |
OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
METHOD FOR EARLY DIAGNOSIS AND PREDICTION OF MACULAR EDEMA IN DIABETIC RETINOPATHY | 2020 |
|
RU2741693C1 |
PREVENTIVE AND THERAPEUTIC AGENT FOR POSTERIOR EYE DISEASES | 2008 |
|
RU2470635C2 |
LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
METHOD OF PROPHYLAXIS OF DIABETIC RETINOPATHY | 1996 |
|
RU2140235C1 |
METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
METHOD FOR TREATMENT OF CATARACT IN PATIENTS WITH ACTIVE NEOVASCULAR DISEASES OF MACULA | 2017 |
|
RU2659144C1 |
Authors
Dates
2016-05-10—Published
2011-12-09—Filed